Immune checkpoint inhibitors (ICIs), including programmed cell death-1 (PD-1) inhibitors such as nivolumab, have revolutionized cancer treatment and brought survival benefits to patients with advanced melanoma. This evidence concerns the gene PDCD1 and melanoma.